Chemistry:Di-β-phenylisopropylamine

From HandWiki
Short description: Central nervous system stimulant

Di-β-phenylisopropylamine
Clinical data
Drug classCentral nervous system stimulant; Serotonin 5-HT1A receptor agonist; norepinephrine reuptake inhibitor; serotonin reuptake inhibitor; adrenergic agonist; prodrug
ATC code
  • none
Pharmacokinetic data
Metabolitesamphetamine[1]
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H23N
Molar mass253.389 g·mol−1
3D model (JSmol)

di-β-phenylisopropylamine also known by the abbreviations DPIA or DPEA, or N,N-Di-β-phenylisopropylamine, and also under the code name Iem-1365, it is a central nervous system stimulant but, above all, a serotonergic agent that also exhibits adrenergic activity; it has been shown to cause central nervous system effects and toxicity similar to those of amphetamine.[2]

DPIA is a secondary amine; structurally, the molecule can be described as comprising a single central amine, to which two isopropyl chains with benzene rings at their ends are attached symmetrically on either side.

Pharmacology

Pharmacodynamics

DPIA is a norepinephrine transporter inhibitor with an IC₅₀ value of 3.1 µM, as well as a dopamine transporter inhibitor with a potency approximately 13 times weaker than that of amphetamine, but 7 times more potent than amphetamine in inhibiting the serotonin transporter, although, unlike amphetamine, DPIA does not exhibit monoamine-releasing activity. It exhibits moderate affinity for 5-HT1A serotonin receptors (Ki = 3.5 µM) and for alpha-1A-adrenoreceptors (Ki = 0.12 µM), and binds to alpha-2A-adrenoreceptors and TAAR1.[2]

In experiments on rodents, DPIA produced the same central effects and toxicity as amphetamine, but was less potent. Interestingly, unlike amphetamine, DPIA caused a reduction in heart rate and blood pressure (exhibiting cardiodepressant properties).[2][3]

Pharmacokinetics

It is thought that the main metabolic pathway for DPIA is its conversion to amphetamine.[1]

References

  1. ↑ 1.0 1.1 "Identification of di(beta-phenylisopropyl)amine as the main ingredient in illicit amphetamine tablets". Annali dell'Istituto Superiore di Sanita 38 (3): 331–335. 2002. PMID 12645186. 
  2. ↑ 2.0 2.1 2.2 "Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA". European Neuropsychopharmacology 59: 9–22. June 2022. doi:10.1016/j.euroneuro.2022.03.006. PMID 35378384. 
  3. ↑ "Pharmacologic and toxicologic effects of di(beta-phenylisopropyl)amine (DPIA) in rats and mice". General Pharmacology 21 (5): 783–790. 1990. doi:10.1016/0306-3623(90)91034-o. PMID 2276597.